Good
Partially Aligned
Patient Risk:
Moderate
Summary
The provided text supports key pregnancy risk messaging (fetal harm/embryo-fetal toxicity) and recommends advising pregnant women and contraception guidance. However, several detailed claims in the AI-generated list (e.g., “Pregnancy Category D,” specific malformations/number of months, and clinical trial/no-case statements) are not supported by the supplied label excerpts and/or are inconsistent with the contraception duration shown.
Category Scores
Accurate Statements
ZEPZELCA can cause fetal harm when administered to a pregnant woman.
Sections 5.5 Embryo-Fetal Toxicity and 8.1 Pregnancy: label states ZEPZELCA can cause fetal harm when administered to a pregnant woman.
Intravenous administration of a single lurbinectedin dose (~0.2 times the 3.2 mg/m^2 clinical dose) to pregnant animals during organogenesis caused 100% embryolethality in rats.
Section 5.5 Embryo-Fetal Toxicity and Section 8.1 Pregnancy (Data/Animal Data).
Advise female patients of reproductive potential to use effective contraception during treatment and for 7 months after the last dose.
Section 8.3 Contraception (Females).
Advise males with a female sexual partner of reproductive potential to use effective contraception during treatment and for 4 months after the last dose.
Section 8.3 Contraception (Males).
Pregnancy testing should be verified prior to initiating ZEPZELCA in females of reproductive potential.
Section 8.3 Pregnancy Testing: “Verify the pregnancy status ... prior to initiating ZEPZELCA.”
Unsupported Statements
Lurbinectedin has not been shown to cause specific structural birth defects in humans.
Not supported by the provided label excerpts (Sections 5.5/8.1/8.3 shown).
Animal studies indicate lurbinectedin may affect development.
General concept is implied by embryo-fetal toxicity data, but the specific wording is not directly supported in the provided excerpts.
In rabbits and rats, lurbinectedin caused embryo-fetal toxicity when given at doses higher than the human dose.
The provided label excerpts describe single-dose findings in pregnant rats at ~0.2 times the human dose; no rabbit data and no “higher than the human dose” statement are present in the excerpts.
In rabbits and rats, lurbinectedin caused malformations when given at doses higher than the human dose.
The provided excerpts describe embryolethality; they do not mention malformations or any rabbit findings.
These observations led the FDA to assign Pregnancy Category D to lurbinectedin.
The supplied label excerpts do not include Pregnancy Category D or any category assignment.
Pregnancy Category D means the risk to the women who use the drug during pregnancy cannot be ruled out.
No Pregnancy Category D definition or category text is present in the supplied label excerpts.
No clinical trials enrolled pregnant women.
Not supported by the provided label excerpts.
No cases of birth defects were reported in spontaneous adverse-event reports.
Not supported by the provided label excerpts.
Contradictions
Low
AI Statement
Women who could become pregnant must use effective contraception during treatment and for at least four months after the last dose.
Label Reference
Section 8.3 Contraception (Females) advises effective contraception for 7 months after the last dose (not at least 4 months).
Important Omissions
Contraception duration for females is specified as 7 months after the last dose (and contraception/testing should be verified prior to initiation).
Importance:
Moderate
The label provides specific embryo-fetal findings in rats (100% post-implantation loss/embryolethality at ~0.2 times the human dose), which are not reflected in the supplied AI list’s focus on “higher than the human dose” and rabbits.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The label supports fetal harm risk and contraception requirements; however, the contraception duration claim for women is contradicted by the excerpt (4 months vs 7 months), which could lead to inadequate risk mitigation if followed.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several pregnancy-related details (Pregnancy Category D, rabbit data, malformations, clinical trial/enrollment and spontaneous report claims) are unsupported by the provided label excerpts; additionally, the female contraception duration is contradicted by the label excerpt (7 months vs at least 4 months).
Suggested Improvement
Limit statements to what is supported in Sections 5.5 and 8.1/8.3 excerpts (fetal harm/embryolethality in rats at ~0.2x dose; contraception duration: females 7 months, males 4 months; verify pregnancy status prior to initiation). Remove or qualify unsupported category/clinical trial/spontaneous-report and rabbit/malformation claims unless additional label sections are provided.